The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results.
Iria Gonzalez
No relevant relationships to disclose
Daniel E. Castellano
No relevant relationships to disclose
Emilio Esteban
No relevant relationships to disclose
Quionia Pérez Arnillas
No relevant relationships to disclose
Javier Munarriz
No relevant relationships to disclose
Begona Campos Balea
No relevant relationships to disclose
Jose Maria Garcia-Bueno
No relevant relationships to disclose
M. Laura Villalobos Leon
No relevant relationships to disclose
Nuria Laínez
No relevant relationships to disclose
Gustavo Rubio
No relevant relationships to disclose
Carmen Santander
No relevant relationships to disclose
Jose David Cumplido Buron
No relevant relationships to disclose
Jose Garcia Sanchez
No relevant relationships to disclose
Almudena Martin
No relevant relationships to disclose
Beatriz Pelaez Lorenzo
No relevant relationships to disclose
Ana Reyes Garcia
No relevant relationships to disclose
Urbano Anido Herranz
No relevant relationships to disclose
Begoña Perez-Valderrama
No relevant relationships to disclose
Jose Maria Yglesias
No relevant relationships to disclose
Joaquim Bellmunt
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi